Date: 2013-01-16
Type of information:
phase: 1
Announcement: initiation
Company: Astex Pharmaceuticals (USA) Cancer Research UK (UK) Cancer Research Technology (CRT) (UK)
Product: AT13148
Action mechanism: AT13148 is a multi-AGC kinase inhibitor that inhibits several enzymes in the PI3K - AKT tumor cell survival pathway including protein kinase B (PKB/AKT) and p70S6K. AT13148 shows a distinct mechanism of action from other AKT inhibitors. Pre-clinical research was published recently (Clin. Cancer Res.; 2012,18(14); 3912-3923). The molecule was originally discovered by scientists on the PKB drug discovery program, a collaboration between Astex Pharmaceuticals, CRT and The Institute of Cancer Research, which ran from 2003 through 2006.
Disease: several undisclosed cancer types
Therapeutic area: Cancer - Oncology
Country: UK
Trial details:
Latest
news: * On January, 16, 2013, Astex Pharmaceuticals announced that collaborators Cancer Research UK and its commercial arm Cancer Research Technology (CRT) are launching a trial of AT13148, an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. The \'master-switch\' experimental drug, owned by Astex Pharmaceuticals, is being studied in a range of cancer types.
Cancer Research UK\'s Drug Development Office (DDO) will fund, manage and sponsor this early-stage Phase I clinical trial of up to 40 patients at The Institute of Cancer Research, London, and The Royal Marsden Hospital.
The drug, AT13148, is one of eight drugs to be developed through Cancer Research UK\'s Clinical Development Partnerships program, which is a joint initiative between the charity\'s DDO and CRT. The program develops promising cancer drugs that pharmaceutical companies do not have the resources to progress through early phase clinical trials to see if they can benefit cancer patients.
